CHICAGO, Ill. and FORT WORTH, Texas — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that new additional and promising patient survival and...
treatment News
CHICAGO, Illinois and FORT WORTH, Texas – Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), provided an update on its Phase 1/2 trial of elraglusib in relapsed/refractory Ewing Sarcoma...
CHICAGO, Ill. and FORT WORTH, Texas — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the publication of new data in Clinical Cancer...
CHICAGO, Ill. and FORT WORTH, Texas — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the end of the Phase 1 portion of...
SAN DIEGO, Calif. and SUZHOU, China — Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco. Details for the poster include:...
CHARLOTTE, N.C. — Adaptin Bio, Inc. (“Adaptin” or the “Company”), a biotechnology company developing precision cancer therapeutics enabled by targeted delivery to the brain and other difficult-to-reach tissues, today announced that the Preston Robert Tisch Brain Tumor Center has granted the first Institutional Review Board (IRB) approval for the Company’s...
SAN DIEGO, Calif. — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE). Additionally, ADARx announced that the U.S. Food and Drug Administration...
LAUSANNE, Switzerland – ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma...
LAUSANNE, Switzerland — ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter study is currently being conducted...
LAUSANNE, Switzerland — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with...